A promising target to fight inflammatory bowel diseases

Posted by Michael Jannicelli | Oct 30, 2023 | Uncategorized | 0 |

Inflammatory bowel diseases (IBDs), such as Crohn’s disease or ulcerative colitis, arise when there is a dysregulation of cell signalling pathways, leading to a chronic inflammatory response. The gut inflammatory response relies on a chain reaction involving several molecules, including RIPK2 — known to be a good target for inhibitors treating IBDs. Researchers from the Cusack group at EMBL Grenoble have provided new insights into the interactions between RIPK2 and XIAP, another molecule involved in the inflammatory response, during the downstream chain reaction. These results, when taken together with previous structural biology studies on RIPK2, offer valuable information for the development of therapeutics to treat inflammatory bowel diseases.

About The Author

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.